NCT02538536View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
DRUG

PBI4050

Trial Locations (5)

Unknown

Vancouver

Halifax

Toronto

Montreal

Sherbrooke

Sponsors
All Listed Sponsors
lead

Liminal BioSciences Ltd.

INDUSTRY